Please try another search
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Glenn P. Sblendorio | 68 | 2023 | Independent Director |
Jon Congleton | 61 | 2020 | CEO & Director |
Brian Taylor Slingsby | 47 | 2019 | Founder & Executive Chairman |
Daphne Karydas | 51 | 2023 | Independent Director |
Derek Paul DiRocco | 43 | 2022 | Independent Director |
James Matthew Luther | - | - | Member of Clinical Advisory Board |
Matthew R. Weir | - | - | Member of Clinical Advisory Board |
Srinivas Akkaraju | 56 | 2021 | Independent Director |
Olivier Litzka | 56 | 2022 | Independent Director |
Joseph Loscalzo | 73 | - | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review